Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Human Immunology

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.humimm.2012.07.329PMID 22836041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma.

  2011cited by this paper
• Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects.

  2010cited by this paper
• Egypt Demographic and Health Survey 2000.

  2009cited by this paper
• Osteopontin: regulation in tumor metastasis

  2008cited by this paper
• Osteopontin as two-sided mediator of intestinal inflammation

  2008cited by this paper
• Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury.

  2007cited by this paper
• Gene modulation for treating liver fibrosis.

  2007cited by this paper
• Opn: key regulator of pDC interferon production

  2006cited by this paper
• L’ostéopontine, une molécule aux multiples facettes

  2005cited by this paper
• [Osteopontin, a multi-faceted molecule].

  2005cited by this paper
• Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice.

  2005cited by this paper
• Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients.

  2004cited by this paper
• Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients.

  2003cited by this paper
• High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation.

  2003cited by this paper
• Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction.

  2003cited by this paper
• Hepatic stellate cells: unique characteristics in cell biology and phenotype.

  2003cited by this paper
• An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus

  2002cited by this paper
• The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease

  2001cited by this paper
• Expression, roles, receptors, and regulation of osteopontin in the kidney.

  2001cited by this paper
• Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis.

  2001cited by this paper
• The functional and clinical roles of osteopontin in cancer and metastasis.

  2001cited by this paper
• Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats.

  2000cited by this paper
• Interaction between the Hepatitis C Virus and the Immune System

  2000cited by this paper
• Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection.

  2000cited by this paper
• Osteopontin augments CD3‐mediated interferon‐γ and CD40 ligand expression by T cells, which results in IL‐12 production from peripheral blood mononuclear cells

  2000cited by this paper
• Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

  2000cited by this paper
• Increased expression of osteopontin in activated Kupffer cells and hepatic macrophages during macrophage migration in Propionibacterium acnes-treated rat liver

  2000cited by this paper
• Natural history of acute hepatitis C

  2000cited by this paper
• Global surveillance and control of hepatitis C

  1999cited by this paper
• Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis.

  1999cited by this paper
• Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

  1999cited by this paper
• Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas.

  1999cited by this paper
• Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

  1999cited by this paper
• Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro.

  1999cited by this paper
• Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

  1999cited by this paper
• Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence

  1999cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Correlation between virus genotype and chronicity rate in acute hepatitis C.

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors

  1997cited by this paper
• Inhibition of the Kupffer cell inflammatory response by acute ethanol: NF-kappa B activation and subsequent cytokine production.

  1996cited by this paper
• Clinical outcomes after transfusion-associated hepatitis C.

  1995cited by this paper
• Structure of the Osteopontin Gene and Its Promoter a

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies.

  1993cited by this paper
• Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene.

  1993cited by this paper
• The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies

  1993cited by this paper
• Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide

  1972cited by this paper

• The Influence of C936T Gene in Wild of the Vascular Endothelial GrowthFactor and Biochemical Variants Analysis for Alpha-Fetoprotein inHepatocellular Carcinoma Patients in Egypt

  2017cites this paper
• Evaluation of Silibinin Enriched Silymarin in Chronic HCV Patients

  2017cites this paper
• A Study of Genetic Alterations in Cancer Progression

  2015cites this paper
• Serum Interferon-Related MicroRNAs as Biomarkers to Predict the Response to Interferon Therapy in Chronic Hepatitis C Genotype 4

  2015cites this paper
• Osteopontin: Versatile modulator of liver diseases

  2014cites this paper
• The potential of the human osteopontin promoter and single-nucleotide polymorphisms for targeted cancer gene therapy.

  2014cites this paper
• Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication.

  2014cites this paper
• Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies

  2014cites this paper
• OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC

  2014cites this paper
• An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer.

  2013cites this paper
• Engineering bioceramic microstructure for customized drug delivery

  2013cites this paper
• Osteopontin promoter polymorphisms at locus ‐443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma

  2013cites this paper